Charter Trust Co. decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 1.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 270,028 shares of the biopharmaceutical company’s stock after selling 3,093 shares during the period. Pfizer comprises 1.1% of Charter Trust Co.’s portfolio, making the stock its 23rd biggest position. Charter Trust Co.’s holdings in Pfizer were worth $9,780,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently bought and sold shares of PFE. Mckinley Capital Management LLC Delaware acquired a new stake in shares of Pfizer in the second quarter valued at approximately $103,000. Herndon Capital Management LLC bought a new position in Pfizer in the second quarter valued at approximately $120,000. Americafirst Capital Management LLC bought a new position in Pfizer in the third quarter valued at approximately $127,000. Private Vista LLC boosted its stake in Pfizer by 2,277.3% in the second quarter. Private Vista LLC now owns 199,317 shares of the biopharmaceutical company’s stock valued at $133,000 after acquiring an additional 190,933 shares during the last quarter. Finally, Lipe & Dalton boosted its stake in Pfizer by 6.9% in the second quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock valued at $155,000 after acquiring an additional 300 shares during the last quarter. 71.41% of the stock is owned by institutional investors.
A number of equities analysts have issued reports on the stock. BMO Capital Markets set a $43.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research note on Tuesday, March 6th. Berenberg Bank set a $36.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a research note on Tuesday, January 30th. UBS set a $42.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research note on Wednesday, January 31st. Leerink Swann raised their price objective on shares of Pfizer from $35.00 to $38.00 and gave the company a “market perform” rating in a research note on Wednesday, January 31st. Finally, Jefferies Group set a $39.00 price objective on shares of Pfizer and gave the company a “hold” rating in a research note on Monday, February 26th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. Pfizer currently has a consensus rating of “Hold” and a consensus price target of $39.40.
In related news, insider Mikael Dolsten sold 69,699 shares of the business’s stock in a transaction on Friday, March 9th. The shares were sold at an average price of $36.59, for a total value of $2,550,286.41. Following the sale, the insider now directly owns 120,784 shares of the company’s stock, valued at approximately $4,419,486.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Kirsten Lund-Jurgensen sold 9,510 shares of the business’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $37.19, for a total transaction of $353,676.90. Following the completion of the sale, the insider now directly owns 36,959 shares in the company, valued at $1,374,505.21. The disclosure for this sale can be found here. Over the last three months, insiders have sold 248,037 shares of company stock worth $9,064,785. Insiders own 0.06% of the company’s stock.
Pfizer stock opened at $36.78 on Monday. The firm has a market cap of $218,946.38, a price-to-earnings ratio of 10.48, a PEG ratio of 2.07 and a beta of 0.91. Pfizer Inc. has a 52-week low of $31.67 and a 52-week high of $39.43. The company has a current ratio of 1.35, a quick ratio of 1.10 and a debt-to-equity ratio of 0.47.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.06. The company had revenue of $13.70 billion for the quarter, compared to analysts’ expectations of $13.67 billion. Pfizer had a net margin of 40.55% and a return on equity of 25.21%. The business’s quarterly revenue was up .6% compared to the same quarter last year. During the same period last year, the firm posted $0.47 earnings per share. research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.
Pfizer announced that its board has approved a stock repurchase plan on Monday, December 18th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to purchase shares of its stock through open market purchases. Shares repurchase plans are generally a sign that the company’s management believes its stock is undervalued.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.